nodes	percent_of_prediction	percent_of_DWPC	metapath
Dantrolene—CYP3A4—prostate cancer	0.257	1	CbGaD
Dantrolene—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0797	0.207	CbGbCtD
Dantrolene—CYP3A4—Bicalutamide—prostate cancer	0.0419	0.109	CbGbCtD
Dantrolene—CYP3A4—Estramustine—prostate cancer	0.0389	0.101	CbGbCtD
Dantrolene—CYP3A4—Flutamide—prostate cancer	0.0347	0.09	CbGbCtD
Dantrolene—CYP3A4—Abiraterone—prostate cancer	0.0347	0.09	CbGbCtD
Dantrolene—CYP3A4—Cabazitaxel—prostate cancer	0.0257	0.0666	CbGbCtD
Dantrolene—CYP3A4—Estrone—prostate cancer	0.0251	0.0651	CbGbCtD
Dantrolene—CYP3A4—Ethinyl Estradiol—prostate cancer	0.0224	0.058	CbGbCtD
Dantrolene—CYP3A4—Conjugated Estrogens—prostate cancer	0.0164	0.0426	CbGbCtD
Dantrolene—CYP3A4—Mitoxantrone—prostate cancer	0.0149	0.0387	CbGbCtD
Dantrolene—CYP3A4—Estradiol—prostate cancer	0.0144	0.0374	CbGbCtD
Dantrolene—CYP3A4—Prednisone—prostate cancer	0.0124	0.0321	CbGbCtD
Dantrolene—RYR3—prostate gland—prostate cancer	0.0101	0.267	CbGeAlD
Dantrolene—CYP3A4—Etoposide—prostate cancer	0.00941	0.0244	CbGbCtD
Dantrolene—CYP3A4—Docetaxel—prostate cancer	0.00861	0.0223	CbGbCtD
Dantrolene—RYR3—seminal vesicle—prostate cancer	0.00851	0.225	CbGeAlD
Dantrolene—RYR1—prostate gland—prostate cancer	0.00722	0.191	CbGeAlD
Dantrolene—CYP3A4—Doxorubicin—prostate cancer	0.00642	0.0166	CbGbCtD
Dantrolene—RYR3—testis—prostate cancer	0.00443	0.117	CbGeAlD
Dantrolene—CYP3A4—urine—prostate cancer	0.0035	0.0926	CbGeAlD
Dantrolene—RYR1—testis—prostate cancer	0.00318	0.0842	CbGeAlD
Dantrolene—CYP3A4—renal system—prostate cancer	0.000856	0.0227	CbGeAlD
Dantrolene—CYP3A4—Metapathway biotransformation—GSTCD—prostate cancer	0.000213	0.00218	CbGpPWpGaD
Dantrolene—CYP3A4—Tamoxifen metabolism—CYP2A6—prostate cancer	0.000212	0.00217	CbGpPWpGaD
Dantrolene—CYP3A4—Tryptophan metabolism—CYP7B1—prostate cancer	0.00021	0.00215	CbGpPWpGaD
Dantrolene—CYP3A4—Constitutive Androstane Receptor Pathway—GSTA2—prostate cancer	0.000207	0.00212	CbGpPWpGaD
Dantrolene—RYR3—Transmembrane transport of small molecules—RXRA—prostate cancer	0.000206	0.00211	CbGpPWpGaD
Dantrolene—CYP3A4—Constitutive Androstane Receptor Pathway—SULT1A1—prostate cancer	0.000205	0.00209	CbGpPWpGaD
Dantrolene—CYP3A4—Estrogen metabolism—NQO1—prostate cancer	0.000202	0.00206	CbGpPWpGaD
Dantrolene—RYR1—Transmembrane transport of small molecules—PRKACB—prostate cancer	0.000201	0.00206	CbGpPWpGaD
Dantrolene—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCG5—prostate cancer	0.000195	0.00199	CbGpPWpGaD
Dantrolene—CYP3A4—Estrogen metabolism—CYP1B1—prostate cancer	0.000194	0.00198	CbGpPWpGaD
Dantrolene—RYR1—Transmembrane transport of small molecules—NCOA2—prostate cancer	0.00019	0.00194	CbGpPWpGaD
Dantrolene—CYP3A4—Xenobiotics—CYP2E1—prostate cancer	0.000188	0.00192	CbGpPWpGaD
Dantrolene—RYR1—Transmembrane transport of small molecules—SLC5A5—prostate cancer	0.000181	0.00185	CbGpPWpGaD
Dantrolene—CYP3A4—Tamoxifen metabolism—CYP2E1—prostate cancer	0.000181	0.00184	CbGpPWpGaD
Dantrolene—CYP3A4—Aflatoxin activation and detoxification—GGT1—prostate cancer	0.00018	0.00183	CbGpPWpGaD
Dantrolene—CYP3A4—Phase 1 - Functionalization of compounds—CYP3A43—prostate cancer	0.000177	0.00181	CbGpPWpGaD
Dantrolene—CYP3A4—Constitutive Androstane Receptor Pathway—SULT2A1—prostate cancer	0.000176	0.0018	CbGpPWpGaD
Dantrolene—CYP3A4—Tamoxifen metabolism—CYP1B1—prostate cancer	0.000171	0.00175	CbGpPWpGaD
Dantrolene—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP7B1—prostate cancer	0.00017	0.00173	CbGpPWpGaD
Dantrolene—CYP3A4—Estrogen metabolism—COMT—prostate cancer	0.000169	0.00173	CbGpPWpGaD
Dantrolene—CYP3A4—Farnesoid X Receptor  Pathway—RXRA—prostate cancer	0.000168	0.00172	CbGpPWpGaD
Dantrolene—CYP3A4—Oxidation by Cytochrome P450—CYP7B1—prostate cancer	0.000168	0.00171	CbGpPWpGaD
Dantrolene—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—prostate cancer	0.000167	0.0017	CbGpPWpGaD
Dantrolene—RYR3—Myometrial Relaxation and Contraction Pathways—IL6—prostate cancer	0.000166	0.0017	CbGpPWpGaD
Dantrolene—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—prostate cancer	0.000161	0.00165	CbGpPWpGaD
Dantrolene—RYR1—Transmembrane transport of small molecules—NCOA1—prostate cancer	0.00016	0.00163	CbGpPWpGaD
Dantrolene—RYR3—Transmembrane transport of small molecules—PPARA—prostate cancer	0.000158	0.00161	CbGpPWpGaD
Dantrolene—CYP3A4—Constitutive Androstane Receptor Pathway—CYP2C19—prostate cancer	0.000157	0.00161	CbGpPWpGaD
Dantrolene—CYP3A4—Estrogen metabolism—GSTM1—prostate cancer	0.000155	0.00158	CbGpPWpGaD
Dantrolene—RYR1—Transmembrane transport of small molecules—RXRA—prostate cancer	0.000152	0.00155	CbGpPWpGaD
Dantrolene—CYP3A4—Constitutive Androstane Receptor Pathway—CYP2A6—prostate cancer	0.000152	0.00155	CbGpPWpGaD
Dantrolene—CYP3A4—Estrogen metabolism—CYP1A1—prostate cancer	0.000147	0.0015	CbGpPWpGaD
Dantrolene—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP3A5—prostate cancer	0.000146	0.00149	CbGpPWpGaD
Dantrolene—CYP3A4—Oxidation by Cytochrome P450—CYP3A5—prostate cancer	0.000144	0.00147	CbGpPWpGaD
Dantrolene—CYP3A4—Tryptophan metabolism—CYP2C18—prostate cancer	0.000142	0.00145	CbGpPWpGaD
Dantrolene—CYP3A4—Irinotecan Pathway—APC—prostate cancer	0.000141	0.00144	CbGpPWpGaD
Dantrolene—CYP3A4—Constitutive Androstane Receptor Pathway—NCOA2—prostate cancer	0.000138	0.00141	CbGpPWpGaD
Dantrolene—CYP3A4—Phase 1 - Functionalization of compounds—CYP7B1—prostate cancer	0.000138	0.00141	CbGpPWpGaD
Dantrolene—CYP3A4—Xenobiotics—CYP1A1—prostate cancer	0.000135	0.00138	CbGpPWpGaD
Dantrolene—CYP3A4—Tamoxifen metabolism—CYP1A1—prostate cancer	0.00013	0.00133	CbGpPWpGaD
Dantrolene—CYP3A4—Cytochrome P450 - arranged by substrate type—TBXAS1—prostate cancer	0.000129	0.00131	CbGpPWpGaD
Dantrolene—RYR3—Transmembrane transport of small molecules—CREBBP—prostate cancer	0.000125	0.00128	CbGpPWpGaD
Dantrolene—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2E1—prostate cancer	0.000123	0.00125	CbGpPWpGaD
Dantrolene—RYR1—Myometrial Relaxation and Contraction Pathways—IL6—prostate cancer	0.000123	0.00125	CbGpPWpGaD
Dantrolene—CYP3A4—Phase 1 - Functionalization of compounds—CYP3A5—prostate cancer	0.000118	0.00121	CbGpPWpGaD
Dantrolene—CYP3A4—Constitutive Androstane Receptor Pathway—NCOA1—prostate cancer	0.000117	0.00119	CbGpPWpGaD
Dantrolene—RYR1—Transmembrane transport of small molecules—PPARA—prostate cancer	0.000116	0.00119	CbGpPWpGaD
Dantrolene—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2C18—prostate cancer	0.000115	0.00117	CbGpPWpGaD
Dantrolene—CYP3A4—Oxidation by Cytochrome P450—CYP2C18—prostate cancer	0.000113	0.00116	CbGpPWpGaD
Dantrolene—CYP3A4—Constitutive Androstane Receptor Pathway—RXRA—prostate cancer	0.000111	0.00113	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—UGT2B17—prostate cancer	0.000105	0.00108	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—UGT2B15—prostate cancer	0.000105	0.00108	CbGpPWpGaD
Dantrolene—CYP3A4—Phase 1 - Functionalization of compounds—TBXAS1—prostate cancer	0.000104	0.00107	CbGpPWpGaD
Dantrolene—Asthenia—Estradiol—prostate cancer	0.000104	0.00047	CcSEcCtD
Dantrolene—CYP3A4—Metapathway biotransformation—UGT2B17—prostate cancer	0.000104	0.00106	CbGpPWpGaD
Dantrolene—Ill-defined disorder—Capecitabine—prostate cancer	0.000103	0.000465	CcSEcCtD
Dantrolene—Pruritus—Estradiol—prostate cancer	0.000103	0.000464	CcSEcCtD
Dantrolene—Dysphagia—Doxorubicin—prostate cancer	0.000103	0.000463	CcSEcCtD
Dantrolene—Leukopenia—Docetaxel—prostate cancer	0.000103	0.000463	CcSEcCtD
Dantrolene—Anaemia—Capecitabine—prostate cancer	0.000103	0.000463	CcSEcCtD
Dantrolene—Pollakiuria—Epirubicin—prostate cancer	0.000102	0.000463	CcSEcCtD
Dantrolene—Eosinophilia—Doxorubicin—prostate cancer	0.000102	0.000459	CcSEcCtD
Dantrolene—Malaise—Capecitabine—prostate cancer	0.0001	0.000452	CcSEcCtD
Dantrolene—Somnolence—Etoposide—prostate cancer	0.0001	0.000452	CcSEcCtD
Dantrolene—Hypersensitivity—Mitoxantrone—prostate cancer	9.97e-05	0.00045	CcSEcCtD
Dantrolene—Diarrhoea—Estradiol—prostate cancer	9.94e-05	0.000449	CcSEcCtD
Dantrolene—Leukopenia—Capecitabine—prostate cancer	9.93e-05	0.000448	CcSEcCtD
Dantrolene—Convulsion—Docetaxel—prostate cancer	9.93e-05	0.000448	CcSEcCtD
Dantrolene—CYP3A4—Biological oxidations—SULT2B1—prostate cancer	9.92e-05	0.00101	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—GSTM3—prostate cancer	9.92e-05	0.00101	CbGpPWpGaD
Dantrolene—Hypertension—Docetaxel—prostate cancer	9.9e-05	0.000447	CcSEcCtD
Dantrolene—Drowsiness—Epirubicin—prostate cancer	9.89e-05	0.000447	CcSEcCtD
Dantrolene—Erythema—Prednisone—prostate cancer	9.88e-05	0.000446	CcSEcCtD
Dantrolene—Decreased appetite—Etoposide—prostate cancer	9.78e-05	0.000442	CcSEcCtD
Dantrolene—CYP3A4—Metapathway biotransformation—GSTM3—prostate cancer	9.78e-05	0.000999	CbGpPWpGaD
Dantrolene—CYP3A4—Metapathway biotransformation—SULT2B1—prostate cancer	9.78e-05	0.000999	CbGpPWpGaD
Dantrolene—Myalgia—Docetaxel—prostate cancer	9.76e-05	0.000441	CcSEcCtD
Dantrolene—Renal failure—Epirubicin—prostate cancer	9.72e-05	0.000439	CcSEcCtD
Dantrolene—Asthenia—Mitoxantrone—prostate cancer	9.71e-05	0.000438	CcSEcCtD
Dantrolene—Fatigue—Etoposide—prostate cancer	9.7e-05	0.000438	CcSEcCtD
Dantrolene—CYP3A4—Tryptophan metabolism—CYP2E1—prostate cancer	9.64e-05	0.000985	CbGpPWpGaD
Dantrolene—Pain—Etoposide—prostate cancer	9.63e-05	0.000435	CcSEcCtD
Dantrolene—Constipation—Etoposide—prostate cancer	9.63e-05	0.000435	CcSEcCtD
Dantrolene—Dizziness—Estradiol—prostate cancer	9.6e-05	0.000434	CcSEcCtD
Dantrolene—Hypertension—Capecitabine—prostate cancer	9.58e-05	0.000433	CcSEcCtD
Dantrolene—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—prostate cancer	9.57e-05	0.000977	CbGpPWpGaD
Dantrolene—Dry mouth—Docetaxel—prostate cancer	9.54e-05	0.000431	CcSEcCtD
Dantrolene—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2C19—prostate cancer	9.5e-05	0.000971	CbGpPWpGaD
Dantrolene—Sweating—Epirubicin—prostate cancer	9.48e-05	0.000428	CcSEcCtD
Dantrolene—Pollakiuria—Doxorubicin—prostate cancer	9.48e-05	0.000428	CcSEcCtD
Dantrolene—Myalgia—Capecitabine—prostate cancer	9.45e-05	0.000427	CcSEcCtD
Dantrolene—Haematuria—Epirubicin—prostate cancer	9.43e-05	0.000426	CcSEcCtD
Dantrolene—Confusional state—Docetaxel—prostate cancer	9.43e-05	0.000426	CcSEcCtD
Dantrolene—CYP3A4—Biological oxidations—CYP3A43—prostate cancer	9.4e-05	0.00096	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—NAT1—prostate cancer	9.4e-05	0.00096	CbGpPWpGaD
Dantrolene—CYP3A4—Oxidation by Cytochrome P450—CYP2C19—prostate cancer	9.38e-05	0.000958	CbGpPWpGaD
Dantrolene—Anaphylactic shock—Docetaxel—prostate cancer	9.35e-05	0.000422	CcSEcCtD
Dantrolene—Discomfort—Capecitabine—prostate cancer	9.33e-05	0.000421	CcSEcCtD
Dantrolene—Vision blurred—Prednisone—prostate cancer	9.32e-05	0.000421	CcSEcCtD
Dantrolene—CYP3A4—Phase 1 - Functionalization of compounds—CYP2C18—prostate cancer	9.3e-05	0.00095	CbGpPWpGaD
Dantrolene—Feeling abnormal—Etoposide—prostate cancer	9.28e-05	0.000419	CcSEcCtD
Dantrolene—CYP3A4—Metapathway biotransformation—CYP3A43—prostate cancer	9.27e-05	0.000947	CbGpPWpGaD
Dantrolene—Diarrhoea—Mitoxantrone—prostate cancer	9.26e-05	0.000418	CcSEcCtD
Dantrolene—Dry mouth—Capecitabine—prostate cancer	9.24e-05	0.000417	CcSEcCtD
Dantrolene—Vomiting—Estradiol—prostate cancer	9.23e-05	0.000417	CcSEcCtD
Dantrolene—RYR1—Transmembrane transport of small molecules—CREBBP—prostate cancer	9.23e-05	0.000943	CbGpPWpGaD
Dantrolene—Gastrointestinal pain—Etoposide—prostate cancer	9.2e-05	0.000416	CcSEcCtD
Dantrolene—Ill-defined disorder—Prednisone—prostate cancer	9.17e-05	0.000414	CcSEcCtD
Dantrolene—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A6—prostate cancer	9.17e-05	0.000937	CbGpPWpGaD
Dantrolene—Thrombocytopenia—Docetaxel—prostate cancer	9.16e-05	0.000414	CcSEcCtD
Dantrolene—Rash—Estradiol—prostate cancer	9.16e-05	0.000413	CcSEcCtD
Dantrolene—Drowsiness—Doxorubicin—prostate cancer	9.15e-05	0.000413	CcSEcCtD
Dantrolene—Dermatitis—Estradiol—prostate cancer	9.15e-05	0.000413	CcSEcCtD
Dantrolene—CYP3A4—Tryptophan metabolism—CYP1B1—prostate cancer	9.14e-05	0.000934	CbGpPWpGaD
Dantrolene—Anaemia—Prednisone—prostate cancer	9.14e-05	0.000412	CcSEcCtD
Dantrolene—Confusional state—Capecitabine—prostate cancer	9.13e-05	0.000412	CcSEcCtD
Dantrolene—Tachycardia—Docetaxel—prostate cancer	9.13e-05	0.000412	CcSEcCtD
Dantrolene—Headache—Estradiol—prostate cancer	9.1e-05	0.000411	CcSEcCtD
Dantrolene—CYP3A4—Oxidation by Cytochrome P450—CYP2A6—prostate cancer	9.05e-05	0.000924	CbGpPWpGaD
Dantrolene—Renal failure—Doxorubicin—prostate cancer	9e-05	0.000406	CcSEcCtD
Dantrolene—Urticaria—Etoposide—prostate cancer	8.94e-05	0.000404	CcSEcCtD
Dantrolene—Haemoglobin—Epirubicin—prostate cancer	8.93e-05	0.000403	CcSEcCtD
Dantrolene—Anorexia—Docetaxel—prostate cancer	8.92e-05	0.000403	CcSEcCtD
Dantrolene—Malaise—Prednisone—prostate cancer	8.91e-05	0.000402	CcSEcCtD
Dantrolene—Abdominal pain—Etoposide—prostate cancer	8.9e-05	0.000402	CcSEcCtD
Dantrolene—Body temperature increased—Etoposide—prostate cancer	8.9e-05	0.000402	CcSEcCtD
Dantrolene—Haemorrhage—Epirubicin—prostate cancer	8.88e-05	0.000401	CcSEcCtD
Dantrolene—Hepatitis—Epirubicin—prostate cancer	8.88e-05	0.000401	CcSEcCtD
Dantrolene—Thrombocytopenia—Capecitabine—prostate cancer	8.87e-05	0.0004	CcSEcCtD
Dantrolene—Tachycardia—Capecitabine—prostate cancer	8.84e-05	0.000399	CcSEcCtD
Dantrolene—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP17A1—prostate cancer	8.78e-05	0.000897	CbGpPWpGaD
Dantrolene—Sweating—Doxorubicin—prostate cancer	8.78e-05	0.000396	CcSEcCtD
Dantrolene—Hyperhidrosis—Capecitabine—prostate cancer	8.76e-05	0.000395	CcSEcCtD
Dantrolene—Haematuria—Doxorubicin—prostate cancer	8.73e-05	0.000394	CcSEcCtD
Dantrolene—CYP3A4—Oxidation by Cytochrome P450—CYP17A1—prostate cancer	8.67e-05	0.000885	CbGpPWpGaD
Dantrolene—Anorexia—Capecitabine—prostate cancer	8.63e-05	0.00039	CcSEcCtD
Dantrolene—Nausea—Estradiol—prostate cancer	8.63e-05	0.000389	CcSEcCtD
Dantrolene—Vomiting—Mitoxantrone—prostate cancer	8.6e-05	0.000388	CcSEcCtD
Dantrolene—CYP3A4—Tryptophan metabolism—CYP19A1—prostate cancer	8.6e-05	0.000878	CbGpPWpGaD
Dantrolene—Convulsion—Prednisone—prostate cancer	8.56e-05	0.000387	CcSEcCtD
Dantrolene—Visual impairment—Epirubicin—prostate cancer	8.56e-05	0.000386	CcSEcCtD
Dantrolene—Hypertension—Prednisone—prostate cancer	8.53e-05	0.000385	CcSEcCtD
Dantrolene—Rash—Mitoxantrone—prostate cancer	8.53e-05	0.000385	CcSEcCtD
Dantrolene—Dermatitis—Mitoxantrone—prostate cancer	8.52e-05	0.000385	CcSEcCtD
Dantrolene—Musculoskeletal discomfort—Docetaxel—prostate cancer	8.52e-05	0.000385	CcSEcCtD
Dantrolene—Headache—Mitoxantrone—prostate cancer	8.48e-05	0.000383	CcSEcCtD
Dantrolene—Insomnia—Docetaxel—prostate cancer	8.46e-05	0.000382	CcSEcCtD
Dantrolene—Myalgia—Prednisone—prostate cancer	8.42e-05	0.00038	CcSEcCtD
Dantrolene—CYP3A4—Cytochrome P450 - arranged by substrate type—NCOA2—prostate cancer	8.37e-05	0.000855	CbGpPWpGaD
Dantrolene—Somnolence—Docetaxel—prostate cancer	8.32e-05	0.000375	CcSEcCtD
Dantrolene—Discomfort—Prednisone—prostate cancer	8.31e-05	0.000375	CcSEcCtD
Dantrolene—Hypersensitivity—Etoposide—prostate cancer	8.29e-05	0.000374	CcSEcCtD
Dantrolene—Haemoglobin—Doxorubicin—prostate cancer	8.26e-05	0.000373	CcSEcCtD
Dantrolene—Musculoskeletal discomfort—Capecitabine—prostate cancer	8.25e-05	0.000373	CcSEcCtD
Dantrolene—Flushing—Epirubicin—prostate cancer	8.24e-05	0.000372	CcSEcCtD
Dantrolene—Dyspepsia—Docetaxel—prostate cancer	8.23e-05	0.000372	CcSEcCtD
Dantrolene—Haemorrhage—Doxorubicin—prostate cancer	8.22e-05	0.000371	CcSEcCtD
Dantrolene—Hepatitis—Doxorubicin—prostate cancer	8.22e-05	0.000371	CcSEcCtD
Dantrolene—Insomnia—Capecitabine—prostate cancer	8.19e-05	0.00037	CcSEcCtD
Dantrolene—Decreased appetite—Docetaxel—prostate cancer	8.13e-05	0.000367	CcSEcCtD
Dantrolene—Asthenia—Etoposide—prostate cancer	8.08e-05	0.000365	CcSEcCtD
Dantrolene—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—prostate cancer	8.07e-05	0.000824	CbGpPWpGaD
Dantrolene—Anaphylactic shock—Prednisone—prostate cancer	8.07e-05	0.000364	CcSEcCtD
Dantrolene—Fatigue—Docetaxel—prostate cancer	8.06e-05	0.000364	CcSEcCtD
Dantrolene—Nausea—Mitoxantrone—prostate cancer	8.04e-05	0.000363	CcSEcCtD
Dantrolene—Constipation—Docetaxel—prostate cancer	8e-05	0.000361	CcSEcCtD
Dantrolene—Pain—Docetaxel—prostate cancer	8e-05	0.000361	CcSEcCtD
Dantrolene—Dyspepsia—Capecitabine—prostate cancer	7.97e-05	0.00036	CcSEcCtD
Dantrolene—Chills—Epirubicin—prostate cancer	7.97e-05	0.00036	CcSEcCtD
Dantrolene—Pruritus—Etoposide—prostate cancer	7.96e-05	0.00036	CcSEcCtD
Dantrolene—Visual impairment—Doxorubicin—prostate cancer	7.92e-05	0.000358	CcSEcCtD
Dantrolene—CYP3A4—Metapathway biotransformation—EPHX1—prostate cancer	7.89e-05	0.000805	CbGpPWpGaD
Dantrolene—Tachycardia—Prednisone—prostate cancer	7.87e-05	0.000355	CcSEcCtD
Dantrolene—Decreased appetite—Capecitabine—prostate cancer	7.87e-05	0.000355	CcSEcCtD
Dantrolene—Fatigue—Capecitabine—prostate cancer	7.81e-05	0.000353	CcSEcCtD
Dantrolene—Hyperhidrosis—Prednisone—prostate cancer	7.8e-05	0.000352	CcSEcCtD
Dantrolene—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2E1—prostate cancer	7.8e-05	0.000796	CbGpPWpGaD
Dantrolene—Pain—Capecitabine—prostate cancer	7.74e-05	0.00035	CcSEcCtD
Dantrolene—Constipation—Capecitabine—prostate cancer	7.74e-05	0.00035	CcSEcCtD
Dantrolene—Erythema—Epirubicin—prostate cancer	7.73e-05	0.000349	CcSEcCtD
Dantrolene—Feeling abnormal—Docetaxel—prostate cancer	7.71e-05	0.000348	CcSEcCtD
Dantrolene—CYP3A4—Phase 1 - Functionalization of compounds—CYP2C19—prostate cancer	7.71e-05	0.000787	CbGpPWpGaD
Dantrolene—Diarrhoea—Etoposide—prostate cancer	7.7e-05	0.000348	CcSEcCtD
Dantrolene—CYP3A4—Oxidation by Cytochrome P450—CYP2E1—prostate cancer	7.69e-05	0.000786	CbGpPWpGaD
Dantrolene—Anorexia—Prednisone—prostate cancer	7.69e-05	0.000347	CcSEcCtD
Dantrolene—Gastrointestinal pain—Docetaxel—prostate cancer	7.65e-05	0.000345	CcSEcCtD
Dantrolene—Flushing—Doxorubicin—prostate cancer	7.63e-05	0.000344	CcSEcCtD
Dantrolene—Tension—Epirubicin—prostate cancer	7.59e-05	0.000343	CcSEcCtD
Dantrolene—Dysgeusia—Epirubicin—prostate cancer	7.57e-05	0.000342	CcSEcCtD
Dantrolene—Nervousness—Epirubicin—prostate cancer	7.51e-05	0.000339	CcSEcCtD
Dantrolene—Back pain—Epirubicin—prostate cancer	7.48e-05	0.000338	CcSEcCtD
Dantrolene—Feeling abnormal—Capecitabine—prostate cancer	7.46e-05	0.000337	CcSEcCtD
Dantrolene—Dizziness—Etoposide—prostate cancer	7.44e-05	0.000336	CcSEcCtD
Dantrolene—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A6—prostate cancer	7.43e-05	0.000759	CbGpPWpGaD
Dantrolene—Gastrointestinal pain—Capecitabine—prostate cancer	7.41e-05	0.000334	CcSEcCtD
Dantrolene—Abdominal pain—Docetaxel—prostate cancer	7.39e-05	0.000334	CcSEcCtD
Dantrolene—Body temperature increased—Docetaxel—prostate cancer	7.39e-05	0.000334	CcSEcCtD
Dantrolene—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—prostate cancer	7.39e-05	0.000755	CbGpPWpGaD
Dantrolene—Chills—Doxorubicin—prostate cancer	7.37e-05	0.000333	CcSEcCtD
Dantrolene—Musculoskeletal discomfort—Prednisone—prostate cancer	7.35e-05	0.000332	CcSEcCtD
Dantrolene—CYP3A4—Biological oxidations—CYP7B1—prostate cancer	7.31e-05	0.000747	CbGpPWpGaD
Dantrolene—Insomnia—Prednisone—prostate cancer	7.3e-05	0.000329	CcSEcCtD
Dantrolene—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—prostate cancer	7.29e-05	0.000745	CbGpPWpGaD
Dantrolene—Vision blurred—Epirubicin—prostate cancer	7.29e-05	0.000329	CcSEcCtD
Dantrolene—CYP3A4—Metapathway biotransformation—CYP7B1—prostate cancer	7.21e-05	0.000737	CbGpPWpGaD
Dantrolene—Urticaria—Capecitabine—prostate cancer	7.19e-05	0.000325	CcSEcCtD
Dantrolene—Ill-defined disorder—Epirubicin—prostate cancer	7.17e-05	0.000324	CcSEcCtD
Dantrolene—Abdominal pain—Capecitabine—prostate cancer	7.16e-05	0.000323	CcSEcCtD
Dantrolene—Body temperature increased—Capecitabine—prostate cancer	7.16e-05	0.000323	CcSEcCtD
Dantrolene—Vomiting—Etoposide—prostate cancer	7.16e-05	0.000323	CcSEcCtD
Dantrolene—Erythema—Doxorubicin—prostate cancer	7.15e-05	0.000323	CcSEcCtD
Dantrolene—Anaemia—Epirubicin—prostate cancer	7.15e-05	0.000323	CcSEcCtD
Dantrolene—CYP3A4—Biological oxidations—SULT1E1—prostate cancer	7.13e-05	0.000728	CbGpPWpGaD
Dantrolene—CYP3A4—Phase 1 - Functionalization of compounds—CYP17A1—prostate cancer	7.12e-05	0.000727	CbGpPWpGaD
Dantrolene—Dyspepsia—Prednisone—prostate cancer	7.1e-05	0.000321	CcSEcCtD
Dantrolene—Rash—Etoposide—prostate cancer	7.1e-05	0.00032	CcSEcCtD
Dantrolene—Dermatitis—Etoposide—prostate cancer	7.09e-05	0.00032	CcSEcCtD
Dantrolene—CYP3A4—Cytochrome P450 - arranged by substrate type—NCOA1—prostate cancer	7.05e-05	0.00072	CbGpPWpGaD
Dantrolene—Headache—Etoposide—prostate cancer	7.05e-05	0.000318	CcSEcCtD
Dantrolene—CYP3A4—Metapathway biotransformation—SULT1E1—prostate cancer	7.03e-05	0.000718	CbGpPWpGaD
Dantrolene—Tension—Doxorubicin—prostate cancer	7.02e-05	0.000317	CcSEcCtD
Dantrolene—Decreased appetite—Prednisone—prostate cancer	7.01e-05	0.000317	CcSEcCtD
Dantrolene—Dysgeusia—Doxorubicin—prostate cancer	7e-05	0.000316	CcSEcCtD
Dantrolene—Malaise—Epirubicin—prostate cancer	6.97e-05	0.000315	CcSEcCtD
Dantrolene—Fatigue—Prednisone—prostate cancer	6.96e-05	0.000314	CcSEcCtD
Dantrolene—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—prostate cancer	6.95e-05	0.00071	CbGpPWpGaD
Dantrolene—Nervousness—Doxorubicin—prostate cancer	6.95e-05	0.000314	CcSEcCtD
Dantrolene—CYP3A4—Tryptophan metabolism—CYP1A1—prostate cancer	6.93e-05	0.000708	CbGpPWpGaD
Dantrolene—Leukopenia—Epirubicin—prostate cancer	6.92e-05	0.000312	CcSEcCtD
Dantrolene—Back pain—Doxorubicin—prostate cancer	6.92e-05	0.000312	CcSEcCtD
Dantrolene—Constipation—Prednisone—prostate cancer	6.9e-05	0.000311	CcSEcCtD
Dantrolene—Hypersensitivity—Docetaxel—prostate cancer	6.89e-05	0.000311	CcSEcCtD
Dantrolene—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—prostate cancer	6.86e-05	0.0007	CbGpPWpGaD
Dantrolene—CYP3A4—Phase 1 - Functionalization of compounds—NCOA2—prostate cancer	6.78e-05	0.000693	CbGpPWpGaD
Dantrolene—Vision blurred—Doxorubicin—prostate cancer	6.74e-05	0.000304	CcSEcCtD
Dantrolene—Asthenia—Docetaxel—prostate cancer	6.71e-05	0.000303	CcSEcCtD
Dantrolene—CYP3A4—Cytochrome P450 - arranged by substrate type—RXRA—prostate cancer	6.71e-05	0.000685	CbGpPWpGaD
Dantrolene—Convulsion—Epirubicin—prostate cancer	6.7e-05	0.000302	CcSEcCtD
Dantrolene—Nausea—Etoposide—prostate cancer	6.69e-05	0.000302	CcSEcCtD
Dantrolene—Hypertension—Epirubicin—prostate cancer	6.67e-05	0.000301	CcSEcCtD
Dantrolene—Hypersensitivity—Capecitabine—prostate cancer	6.67e-05	0.000301	CcSEcCtD
Dantrolene—Feeling abnormal—Prednisone—prostate cancer	6.65e-05	0.0003	CcSEcCtD
Dantrolene—Ill-defined disorder—Doxorubicin—prostate cancer	6.64e-05	0.0003	CcSEcCtD
Dantrolene—Pruritus—Docetaxel—prostate cancer	6.62e-05	0.000299	CcSEcCtD
Dantrolene—Anaemia—Doxorubicin—prostate cancer	6.61e-05	0.000298	CcSEcCtD
Dantrolene—Gastrointestinal pain—Prednisone—prostate cancer	6.6e-05	0.000298	CcSEcCtD
Dantrolene—Myalgia—Epirubicin—prostate cancer	6.58e-05	0.000297	CcSEcCtD
Dantrolene—Discomfort—Epirubicin—prostate cancer	6.5e-05	0.000294	CcSEcCtD
Dantrolene—Asthenia—Capecitabine—prostate cancer	6.5e-05	0.000293	CcSEcCtD
Dantrolene—Malaise—Doxorubicin—prostate cancer	6.45e-05	0.000291	CcSEcCtD
Dantrolene—Dry mouth—Epirubicin—prostate cancer	6.44e-05	0.000291	CcSEcCtD
Dantrolene—Urticaria—Prednisone—prostate cancer	6.41e-05	0.000289	CcSEcCtD
Dantrolene—Pruritus—Capecitabine—prostate cancer	6.41e-05	0.000289	CcSEcCtD
Dantrolene—Leukopenia—Doxorubicin—prostate cancer	6.4e-05	0.000289	CcSEcCtD
Dantrolene—Diarrhoea—Docetaxel—prostate cancer	6.4e-05	0.000289	CcSEcCtD
Dantrolene—Abdominal pain—Prednisone—prostate cancer	6.38e-05	0.000288	CcSEcCtD
Dantrolene—Body temperature increased—Prednisone—prostate cancer	6.38e-05	0.000288	CcSEcCtD
Dantrolene—Confusional state—Epirubicin—prostate cancer	6.36e-05	0.000287	CcSEcCtD
Dantrolene—CYP3A4—Phase 1 - Functionalization of compounds—CYP2E1—prostate cancer	6.32e-05	0.000646	CbGpPWpGaD
Dantrolene—Anaphylactic shock—Epirubicin—prostate cancer	6.31e-05	0.000285	CcSEcCtD
Dantrolene—CYP3A4—Biological oxidations—CYP3A5—prostate cancer	6.27e-05	0.000641	CbGpPWpGaD
Dantrolene—Convulsion—Doxorubicin—prostate cancer	6.2e-05	0.00028	CcSEcCtD
Dantrolene—Diarrhoea—Capecitabine—prostate cancer	6.2e-05	0.00028	CcSEcCtD
Dantrolene—CYP3A4—Metapathway biotransformation—CYP3A5—prostate cancer	6.19e-05	0.000632	CbGpPWpGaD
Dantrolene—Dizziness—Docetaxel—prostate cancer	6.19e-05	0.000279	CcSEcCtD
Dantrolene—Thrombocytopenia—Epirubicin—prostate cancer	6.18e-05	0.000279	CcSEcCtD
Dantrolene—Hypertension—Doxorubicin—prostate cancer	6.18e-05	0.000279	CcSEcCtD
Dantrolene—Tachycardia—Epirubicin—prostate cancer	6.16e-05	0.000278	CcSEcCtD
Dantrolene—Hyperhidrosis—Epirubicin—prostate cancer	6.1e-05	0.000275	CcSEcCtD
Dantrolene—Myalgia—Doxorubicin—prostate cancer	6.09e-05	0.000275	CcSEcCtD
Dantrolene—CYP3A4—Biological oxidations—GSTA3—prostate cancer	6.06e-05	0.000619	CbGpPWpGaD
Dantrolene—Discomfort—Doxorubicin—prostate cancer	6.02e-05	0.000272	CcSEcCtD
Dantrolene—Anorexia—Epirubicin—prostate cancer	6.01e-05	0.000272	CcSEcCtD
Dantrolene—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—prostate cancer	5.99e-05	0.000612	CbGpPWpGaD
Dantrolene—Dizziness—Capecitabine—prostate cancer	5.99e-05	0.00027	CcSEcCtD
Dantrolene—CYP3A4—Metapathway biotransformation—GSTA3—prostate cancer	5.98e-05	0.00061	CbGpPWpGaD
Dantrolene—Dry mouth—Doxorubicin—prostate cancer	5.96e-05	0.000269	CcSEcCtD
Dantrolene—Vomiting—Docetaxel—prostate cancer	5.95e-05	0.000269	CcSEcCtD
Dantrolene—Hypersensitivity—Prednisone—prostate cancer	5.94e-05	0.000268	CcSEcCtD
Dantrolene—Rash—Docetaxel—prostate cancer	5.9e-05	0.000266	CcSEcCtD
Dantrolene—Dermatitis—Docetaxel—prostate cancer	5.89e-05	0.000266	CcSEcCtD
Dantrolene—Confusional state—Doxorubicin—prostate cancer	5.89e-05	0.000266	CcSEcCtD
Dantrolene—Headache—Docetaxel—prostate cancer	5.86e-05	0.000265	CcSEcCtD
Dantrolene—Anaphylactic shock—Doxorubicin—prostate cancer	5.84e-05	0.000264	CcSEcCtD
Dantrolene—Asthenia—Prednisone—prostate cancer	5.79e-05	0.000261	CcSEcCtD
Dantrolene—Vomiting—Capecitabine—prostate cancer	5.76e-05	0.00026	CcSEcCtD
Dantrolene—Musculoskeletal discomfort—Epirubicin—prostate cancer	5.75e-05	0.00026	CcSEcCtD
Dantrolene—CYP3A4—Phase 1 - Functionalization of compounds—NCOA1—prostate cancer	5.72e-05	0.000584	CbGpPWpGaD
Dantrolene—Thrombocytopenia—Doxorubicin—prostate cancer	5.72e-05	0.000258	CcSEcCtD
Dantrolene—Rash—Capecitabine—prostate cancer	5.71e-05	0.000258	CcSEcCtD
Dantrolene—Pruritus—Prednisone—prostate cancer	5.71e-05	0.000258	CcSEcCtD
Dantrolene—Insomnia—Epirubicin—prostate cancer	5.71e-05	0.000258	CcSEcCtD
Dantrolene—Dermatitis—Capecitabine—prostate cancer	5.71e-05	0.000258	CcSEcCtD
Dantrolene—Tachycardia—Doxorubicin—prostate cancer	5.7e-05	0.000257	CcSEcCtD
Dantrolene—Headache—Capecitabine—prostate cancer	5.67e-05	0.000256	CcSEcCtD
Dantrolene—Hyperhidrosis—Doxorubicin—prostate cancer	5.64e-05	0.000255	CcSEcCtD
Dantrolene—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—prostate cancer	5.63e-05	0.000575	CbGpPWpGaD
Dantrolene—Somnolence—Epirubicin—prostate cancer	5.61e-05	0.000253	CcSEcCtD
Dantrolene—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—prostate cancer	5.6e-05	0.000572	CbGpPWpGaD
Dantrolene—Anorexia—Doxorubicin—prostate cancer	5.56e-05	0.000251	CcSEcCtD
Dantrolene—Nausea—Docetaxel—prostate cancer	5.56e-05	0.000251	CcSEcCtD
Dantrolene—Dyspepsia—Epirubicin—prostate cancer	5.55e-05	0.000251	CcSEcCtD
Dantrolene—CYP3A4—Biological oxidations—TBXAS1—prostate cancer	5.54e-05	0.000566	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—GSTA4—prostate cancer	5.54e-05	0.000566	CbGpPWpGaD
Dantrolene—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—prostate cancer	5.53e-05	0.000565	CbGpPWpGaD
Dantrolene—Diarrhoea—Prednisone—prostate cancer	5.52e-05	0.000249	CcSEcCtD
Dantrolene—Decreased appetite—Epirubicin—prostate cancer	5.48e-05	0.000248	CcSEcCtD
Dantrolene—CYP3A4—Metapathway biotransformation—GSTA4—prostate cancer	5.47e-05	0.000558	CbGpPWpGaD
Dantrolene—Fatigue—Epirubicin—prostate cancer	5.44e-05	0.000246	CcSEcCtD
Dantrolene—CYP3A4—Phase 1 - Functionalization of compounds—RXRA—prostate cancer	5.44e-05	0.000555	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—GSTA2—prostate cancer	5.4e-05	0.000552	CbGpPWpGaD
Dantrolene—Constipation—Epirubicin—prostate cancer	5.4e-05	0.000244	CcSEcCtD
Dantrolene—Pain—Epirubicin—prostate cancer	5.4e-05	0.000244	CcSEcCtD
Dantrolene—Nausea—Capecitabine—prostate cancer	5.38e-05	0.000243	CcSEcCtD
Dantrolene—Dizziness—Prednisone—prostate cancer	5.33e-05	0.000241	CcSEcCtD
Dantrolene—CYP3A4—Biological oxidations—SULT1A1—prostate cancer	5.33e-05	0.000545	CbGpPWpGaD
Dantrolene—Musculoskeletal discomfort—Doxorubicin—prostate cancer	5.32e-05	0.00024	CcSEcCtD
Dantrolene—Insomnia—Doxorubicin—prostate cancer	5.28e-05	0.000238	CcSEcCtD
Dantrolene—CYP3A4—Metapathway biotransformation—SULT1A1—prostate cancer	5.26e-05	0.000537	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—GSTA1—prostate cancer	5.21e-05	0.000532	CbGpPWpGaD
Dantrolene—Feeling abnormal—Epirubicin—prostate cancer	5.2e-05	0.000235	CcSEcCtD
Dantrolene—Somnolence—Doxorubicin—prostate cancer	5.19e-05	0.000234	CcSEcCtD
Dantrolene—Gastrointestinal pain—Epirubicin—prostate cancer	5.16e-05	0.000233	CcSEcCtD
Dantrolene—CYP3A4—Biological oxidations—GSTO1—prostate cancer	5.15e-05	0.000526	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—NAT2—prostate cancer	5.15e-05	0.000526	CbGpPWpGaD
Dantrolene—Dyspepsia—Doxorubicin—prostate cancer	5.14e-05	0.000232	CcSEcCtD
Dantrolene—Vomiting—Prednisone—prostate cancer	5.13e-05	0.000232	CcSEcCtD
Dantrolene—Rash—Prednisone—prostate cancer	5.09e-05	0.00023	CcSEcCtD
Dantrolene—Dermatitis—Prednisone—prostate cancer	5.08e-05	0.000229	CcSEcCtD
Dantrolene—CYP3A4—Metapathway biotransformation—GSTO1—prostate cancer	5.08e-05	0.000519	CbGpPWpGaD
Dantrolene—CYP3A4—Metapathway biotransformation—NAT2—prostate cancer	5.08e-05	0.000519	CbGpPWpGaD
Dantrolene—Decreased appetite—Doxorubicin—prostate cancer	5.07e-05	0.000229	CcSEcCtD
Dantrolene—Headache—Prednisone—prostate cancer	5.05e-05	0.000228	CcSEcCtD
Dantrolene—Fatigue—Doxorubicin—prostate cancer	5.03e-05	0.000227	CcSEcCtD
Dantrolene—Urticaria—Epirubicin—prostate cancer	5.01e-05	0.000226	CcSEcCtD
Dantrolene—Pain—Doxorubicin—prostate cancer	4.99e-05	0.000225	CcSEcCtD
Dantrolene—Constipation—Doxorubicin—prostate cancer	4.99e-05	0.000225	CcSEcCtD
Dantrolene—Body temperature increased—Epirubicin—prostate cancer	4.99e-05	0.000225	CcSEcCtD
Dantrolene—Abdominal pain—Epirubicin—prostate cancer	4.99e-05	0.000225	CcSEcCtD
Dantrolene—CYP3A4—Biological oxidations—CYP2C18—prostate cancer	4.94e-05	0.000504	CbGpPWpGaD
Dantrolene—CYP3A4—Metapathway biotransformation—CYP2C18—prostate cancer	4.87e-05	0.000498	CbGpPWpGaD
Dantrolene—Feeling abnormal—Doxorubicin—prostate cancer	4.81e-05	0.000217	CcSEcCtD
Dantrolene—Nausea—Prednisone—prostate cancer	4.79e-05	0.000216	CcSEcCtD
Dantrolene—Gastrointestinal pain—Doxorubicin—prostate cancer	4.77e-05	0.000216	CcSEcCtD
Dantrolene—Hypersensitivity—Epirubicin—prostate cancer	4.65e-05	0.00021	CcSEcCtD
Dantrolene—Urticaria—Doxorubicin—prostate cancer	4.64e-05	0.000209	CcSEcCtD
Dantrolene—Body temperature increased—Doxorubicin—prostate cancer	4.61e-05	0.000208	CcSEcCtD
Dantrolene—Abdominal pain—Doxorubicin—prostate cancer	4.61e-05	0.000208	CcSEcCtD
Dantrolene—CYP3A4—Biological oxidations—SULT2A1—prostate cancer	4.59e-05	0.000469	CbGpPWpGaD
Dantrolene—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—prostate cancer	4.54e-05	0.000464	CbGpPWpGaD
Dantrolene—CYP3A4—Metapathway biotransformation—SULT2A1—prostate cancer	4.53e-05	0.000463	CbGpPWpGaD
Dantrolene—Asthenia—Epirubicin—prostate cancer	4.53e-05	0.000204	CcSEcCtD
Dantrolene—Pruritus—Epirubicin—prostate cancer	4.46e-05	0.000202	CcSEcCtD
Dantrolene—CYP3A4—Metapathway biotransformation—GPX3—prostate cancer	4.32e-05	0.000441	CbGpPWpGaD
Dantrolene—Diarrhoea—Epirubicin—prostate cancer	4.32e-05	0.000195	CcSEcCtD
Dantrolene—Hypersensitivity—Doxorubicin—prostate cancer	4.3e-05	0.000194	CcSEcCtD
Dantrolene—CYP3A4—Tryptophan metabolism—MDM2—prostate cancer	4.27e-05	0.000437	CbGpPWpGaD
Dantrolene—Asthenia—Doxorubicin—prostate cancer	4.19e-05	0.000189	CcSEcCtD
Dantrolene—Dizziness—Epirubicin—prostate cancer	4.17e-05	0.000188	CcSEcCtD
Dantrolene—Pruritus—Doxorubicin—prostate cancer	4.13e-05	0.000186	CcSEcCtD
Dantrolene—CYP3A4—Biological oxidations—HPGDS—prostate cancer	4.12e-05	0.000421	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—CYP2C19—prostate cancer	4.09e-05	0.000418	CbGpPWpGaD
Dantrolene—CYP3A4—Metapathway biotransformation—CYP2C19—prostate cancer	4.04e-05	0.000412	CbGpPWpGaD
Dantrolene—Vomiting—Epirubicin—prostate cancer	4.01e-05	0.000181	CcSEcCtD
Dantrolene—CYP3A4—Biological oxidations—GSTT1—prostate cancer	3.99e-05	0.000408	CbGpPWpGaD
Dantrolene—Diarrhoea—Doxorubicin—prostate cancer	3.99e-05	0.00018	CcSEcCtD
Dantrolene—Rash—Epirubicin—prostate cancer	3.98e-05	0.00018	CcSEcCtD
Dantrolene—Dermatitis—Epirubicin—prostate cancer	3.97e-05	0.000179	CcSEcCtD
Dantrolene—Headache—Epirubicin—prostate cancer	3.95e-05	0.000178	CcSEcCtD
Dantrolene—CYP3A4—Biological oxidations—CYP2A6—prostate cancer	3.95e-05	0.000403	CbGpPWpGaD
Dantrolene—Dizziness—Doxorubicin—prostate cancer	3.86e-05	0.000174	CcSEcCtD
Dantrolene—CYP3A4—Metapathway biotransformation—AKR1C3—prostate cancer	3.79e-05	0.000387	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—CYP17A1—prostate cancer	3.78e-05	0.000386	CbGpPWpGaD
Dantrolene—Nausea—Epirubicin—prostate cancer	3.75e-05	0.000169	CcSEcCtD
Dantrolene—CYP3A4—Metapathway biotransformation—CYP17A1—prostate cancer	3.73e-05	0.000381	CbGpPWpGaD
Dantrolene—Vomiting—Doxorubicin—prostate cancer	3.71e-05	0.000168	CcSEcCtD
Dantrolene—Rash—Doxorubicin—prostate cancer	3.68e-05	0.000166	CcSEcCtD
Dantrolene—Dermatitis—Doxorubicin—prostate cancer	3.68e-05	0.000166	CcSEcCtD
Dantrolene—Headache—Doxorubicin—prostate cancer	3.66e-05	0.000165	CcSEcCtD
Dantrolene—CYP3A4—Biological oxidations—NCOA2—prostate cancer	3.6e-05	0.000368	CbGpPWpGaD
Dantrolene—Nausea—Doxorubicin—prostate cancer	3.47e-05	0.000157	CcSEcCtD
Dantrolene—CYP3A4—Biological oxidations—CYP2E1—prostate cancer	3.36e-05	0.000343	CbGpPWpGaD
Dantrolene—CYP3A4—Metapathway biotransformation—CYP2E1—prostate cancer	3.31e-05	0.000338	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—CYP1B1—prostate cancer	3.18e-05	0.000325	CbGpPWpGaD
Dantrolene—CYP3A4—Metapathway biotransformation—CYP1B1—prostate cancer	3.14e-05	0.000321	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—GGT1—prostate cancer	3.08e-05	0.000315	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—NCOA1—prostate cancer	3.04e-05	0.00031	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—CYP19A1—prostate cancer	2.99e-05	0.000306	CbGpPWpGaD
Dantrolene—CYP3A4—Metapathway biotransformation—CYP19A1—prostate cancer	2.95e-05	0.000301	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—RXRA—prostate cancer	2.89e-05	0.000295	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—COMT—prostate cancer	2.78e-05	0.000284	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—GSTP1—prostate cancer	2.77e-05	0.000283	CbGpPWpGaD
Dantrolene—CYP3A4—Metapathway biotransformation—COMT—prostate cancer	2.74e-05	0.00028	CbGpPWpGaD
Dantrolene—CYP3A4—Metapathway biotransformation—GSTP1—prostate cancer	2.73e-05	0.000279	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—GSTM1—prostate cancer	2.54e-05	0.00026	CbGpPWpGaD
Dantrolene—CYP3A4—Metapathway biotransformation—GSTM1—prostate cancer	2.51e-05	0.000256	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—CYP1A1—prostate cancer	2.41e-05	0.000246	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—HAO1—prostate cancer	2.38e-05	0.000243	CbGpPWpGaD
Dantrolene—CYP3A4—Metapathway biotransformation—CYP1A1—prostate cancer	2.38e-05	0.000243	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—CSAD—prostate cancer	1.94e-05	0.000198	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PSAT1—prostate cancer	1.94e-05	0.000198	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—ADI1—prostate cancer	1.94e-05	0.000198	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—TST—prostate cancer	1.94e-05	0.000198	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—CBR1—prostate cancer	1.94e-05	0.000198	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—GRHL1—prostate cancer	1.94e-05	0.000198	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—CKMT2—prostate cancer	1.8e-05	0.000184	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—GRHPR—prostate cancer	1.8e-05	0.000184	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—UGT2B15—prostate cancer	1.8e-05	0.000184	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—UGT2B17—prostate cancer	1.8e-05	0.000184	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PGAM2—prostate cancer	1.7e-05	0.000173	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—GSTM3—prostate cancer	1.7e-05	0.000173	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—AOX1—prostate cancer	1.7e-05	0.000173	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—SULT2B1—prostate cancer	1.7e-05	0.000173	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—RFK—prostate cancer	1.7e-05	0.000173	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—NAGLU—prostate cancer	1.7e-05	0.000173	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—MBTPS1—prostate cancer	1.7e-05	0.000173	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—CYP3A43—prostate cancer	1.61e-05	0.000164	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—AMACR—prostate cancer	1.61e-05	0.000164	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—DEGS1—prostate cancer	1.61e-05	0.000164	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—SRD5A2—prostate cancer	1.61e-05	0.000164	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—NAT1—prostate cancer	1.61e-05	0.000164	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—HSD17B1—prostate cancer	1.53e-05	0.000157	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—B4GALT4—prostate cancer	1.37e-05	0.00014	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—HPGD—prostate cancer	1.37e-05	0.00014	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—TNFRSF21—prostate cancer	1.29e-05	0.000131	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—MTAP—prostate cancer	1.25e-05	0.000128	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—CYP7B1—prostate cancer	1.25e-05	0.000128	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—SULT1E1—prostate cancer	1.22e-05	0.000124	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—SRD5A1—prostate cancer	1.22e-05	0.000124	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—ACSL4—prostate cancer	1.16e-05	0.000119	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—HSD17B3—prostate cancer	1.16e-05	0.000119	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—UMPS—prostate cancer	1.11e-05	0.000114	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PHGDH—prostate cancer	1.11e-05	0.000114	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—ARG2—prostate cancer	1.11e-05	0.000114	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—LDHB—prostate cancer	1.09e-05	0.000112	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—CYP3A5—prostate cancer	1.07e-05	0.00011	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PDHA1—prostate cancer	1.04e-05	0.000106	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—TCN2—prostate cancer	1.04e-05	0.000106	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—GSTA3—prostate cancer	1.04e-05	0.000106	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—UCP3—prostate cancer	1.04e-05	0.000106	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—HSD3B1—prostate cancer	9.89e-06	0.000101	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—SLC22A3—prostate cancer	9.89e-06	0.000101	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—GSTA4—prostate cancer	9.48e-06	9.68e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—TBXAS1—prostate cancer	9.48e-06	9.68e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—GSTA2—prostate cancer	9.24e-06	9.43e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—ABCG5—prostate cancer	9.12e-06	9.32e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—SULT1A1—prostate cancer	9.12e-06	9.32e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—GSTA1—prostate cancer	8.91e-06	9.1e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—GSTO1—prostate cancer	8.81e-06	9e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—HSD3B2—prostate cancer	8.81e-06	9e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—NAT2—prostate cancer	8.81e-06	9e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PLCB2—prostate cancer	8.45e-06	8.63e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—CYP2C18—prostate cancer	8.45e-06	8.63e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—LRP2—prostate cancer	8.45e-06	8.63e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—P4HB—prostate cancer	8.28e-06	8.46e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—SLC22A1—prostate cancer	8.06e-06	8.23e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—SULT2A1—prostate cancer	7.85e-06	8.02e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—MED12—prostate cancer	7.73e-06	7.89e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—GNG5—prostate cancer	7.66e-06	7.83e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—NCOA3—prostate cancer	7.38e-06	7.54e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—HPGDS—prostate cancer	7.04e-06	7.19e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—CYP2C19—prostate cancer	7e-06	7.15e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—ACHE—prostate cancer	6.83e-06	6.98e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—GSTT1—prostate cancer	6.83e-06	6.98e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—CYP2A6—prostate cancer	6.75e-06	6.9e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—AKR1C3—prostate cancer	6.57e-06	6.71e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PRKACB—prostate cancer	6.53e-06	6.67e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—CYP17A1—prostate cancer	6.47e-06	6.6e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—NCOA2—prostate cancer	6.16e-06	6.29e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—SLC5A5—prostate cancer	5.88e-06	6e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—CYP2E1—prostate cancer	5.74e-06	5.86e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—NQO1—prostate cancer	5.68e-06	5.8e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—TH—prostate cancer	5.6e-06	5.71e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—CYP1B1—prostate cancer	5.44e-06	5.56e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—GGT1—prostate cancer	5.27e-06	5.38e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—NCOA1—prostate cancer	5.19e-06	5.3e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—CYP19A1—prostate cancer	5.12e-06	5.23e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—RXRA—prostate cancer	4.94e-06	5.04e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—COMT—prostate cancer	4.76e-06	4.86e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—GSTP1—prostate cancer	4.74e-06	4.84e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—ITPR1—prostate cancer	4.66e-06	4.76e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—TYMS—prostate cancer	4.4e-06	4.5e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—GSTM1—prostate cancer	4.35e-06	4.44e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—LPL—prostate cancer	4.27e-06	4.36e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—CYP1A1—prostate cancer	4.13e-06	4.21e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—ERCC2—prostate cancer	4.09e-06	4.18e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—MTHFR—prostate cancer	3.85e-06	3.93e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PPARA—prostate cancer	3.77e-06	3.85e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—CAV1—prostate cancer	3.55e-06	3.62e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PIK3CG—prostate cancer	3.23e-06	3.3e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—INS—prostate cancer	3.06e-06	3.12e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—CREBBP—prostate cancer	3e-06	3.06e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PIK3CD—prostate cancer	2.84e-06	2.9e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—NOS3—prostate cancer	2.68e-06	2.74e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PIK3CB—prostate cancer	2.48e-06	2.53e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PTGS2—prostate cancer	2.45e-06	2.51e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PTEN—prostate cancer	2.14e-06	2.19e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—EP300—prostate cancer	2.04e-06	2.08e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PIK3CA—prostate cancer	1.51e-06	1.54e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—AKT1—prostate cancer	1.23e-06	1.26e-05	CbGpPWpGaD
